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 2 
Abstract  34 
 35 
Background: Late-onset Alzheimer’s Disease (AD) is highly heritable. The effect of 36 
many common genetic variants, single nucleotide polymorphisms (SNPs) confer risk. 37 
Variants are clustered in areas of biology, notably immunity and inflammation, 38 
cholesterol metabolism, endocytosis and ubiquitination. Polygenic scores (PRS), 39 
which weight the sum of an individual’s risk alleles, have been used to draw 40 
inferences about the pathological processes underpinning AD. 41 
 42 
Objective: This paper aims to systematically review how AD PRS are being used to 43 
study a range of outcomes and phenotypes related to neurodegeneration. 44 
 45 
Methods: We searched the literature from July 2008-July 2018 following PRISMA 46 
guidelines.  47 
 48 
Results: 57 studies met criteria. The AD PRS can distinguish AD cases from 49 
controls. The ability of AD PRS to predict conversion from Mild Cognitive Impairment 50 
(MCI) to AD was less clear. There was strong evidence of association between AD 51 
PRS and cognitive impairment. AD PRS were correlated with a number of biological 52 
phenotypes associated with AD pathology, such as neuroimaging changes and 53 
amyloid and tau measures. Pathway-specific polygenic scores were also associated 54 
with AD-related biologically relevant phenotypes. 55 
 56 
Conclusion: PRS can predict AD effectively and are associated with cognitive 57 
impairment. There is also evidence of association between AD PRS and other 58 
phenotypes relevant to neurodegeneration. The associations between pathway 59 
specific polygenic scores and phenotypic changes may allow us to define the biology 60 
of the disease in individuals and indicate who may benefit from specific treatments. 61 
Longitudinal cohort studies are required to test the ability of PGS to delineate 62 
pathway-specific disease activity. 63 
 64 
 65 
 66 
 67 
 3 
INTRODUCTION 68 
 69 
Alzheimer’s Disease (AD) is a common neurodegenerative condition affecting people 70 
in later life. The heritability of late-onset AD is estimated to be almost 75% [1]. 71 
Genome-wide association studies (GWAS) have identified a number of loci 72 
associated with AD. The largest meta-analysis to date reported 25 loci associated 73 
with increased risk for AD at genome-wide significant level [2]. These common 74 
genetic variants, known as single nucleotide polymorphisms (SNPs), have only a 75 
small effect on disease risk.  76 
 77 
Polygenic risk scores (PRS) sum the weighted allelic dosages across the genome, 78 
and have allowed the exploration of how genetic risk for AD is manifest in different 79 
populations [3]. However, genetic score methodology varies greatly between studies. 80 
For example, Escott-Price et al. analysed over 200,000 SNPs, including APOE and 81 
reported an area under the curve (AUC) value of 0.84 [4] whereas Tosto et al. used 82 
only 21 SNPs excluding APOE resulting in an AUC of 0.57 [5]. 83 
 84 
As GWAS allows all variants in the genome to be tested for association 85 
simultaneously without any a priori hypothesis, they have implicated a number of 86 
areas of biology previously unconnected to AD. Pathway analyses of genome-wide 87 
association data have shown that the disease processes that underpin AD are highly 88 
complex, involving a number of biological processes, including immunity, lipid 89 
metabolism, tau binding proteins, and amyloid precursor protein metabolism [2,6].  90 
 91 
Since the PRS approach was first described, many studies have investigated 92 
whether AD PRS are associated with a wide variety of phenotypes. To summarize 93 
this literature, we undertook a systematic review to identify studies that have used a 94 
PRS approach to investigate phenotypes associated with genetic risk for AD. 95 
 96 
METHODS 97 
 98 
The review was conducted in accordance with the PRISMA guidelines for systematic 99 
reviews [7].   100 
 101 
 4 
Search strategy 102 
We searched MEDLINE, PSYCHINFO and EMBASE literature from July 2008-July 103 
2018. We used a list of predetermined search terms listed in Supplementary 104 
Materials Table 1, and also manually searched the reference lists of relevant articles.  105 
 106 
Inclusion criteria: 107 
• Longitudinal, cross-sectional or case-control studies including genotyped data 108 
• Validated risk loci for AD identified and combined into a PRS 109 
• Reported associations with AD case/control status or another phenotype 110 
Exclusion criteria: 111 
• Studies reporting associations with family history only 112 
• Studies reporting on genetic risk for other conditions or loci that have not been 113 
previously shown to increase risk of AD  114 
• Studies reporting the effect of only one locus or gene (e.g. APOE), or APOE 115 
combined with non-genetic risk factors  116 
• Non-English publications (in the absence of resources to make, or an existing 117 
translation). 118 
 119 
Article selection 120 
 121 
All articles selected for inclusion were original research reports written in English. 122 
The design of the studies was cross-sectional, longitudinal or observational. The 123 
initial search was conducted by NM. Based on the eligibility criteria, two reviewers 124 
(JH and SM) independently selected studies. Any discrepancies were resolved by a 125 
third reviewer (VEP).  126 
 127 
Data extraction 128 
 129 
The reviewers (JH and SM) extracted data from the studies independently and in 130 
duplicate. The extracts included: 1) the type of study, 2) the discovery sample (study 131 
name, sample size and number of cases), 3) the target sample (study name, sample 132 
size, and case number), 4) the number of SNPs included in the PRS (see data 133 
extraction form in Supplementary Material). Results that were reported in separate 134 
papers were only included once.  135 
 5 
 136 
RESULTS 137 
 138 
Search results 139 
 140 
The initial search produced 4717 articles (see PRISMA flow chart in Figure 1). 1322 141 
were removed as duplicates. A further 3275 were excluded based on their title and 142 
abstract. The reviewers (JH and SM) reviewed the full text of the remaining 120 143 
articles and applied strict inclusion criteria, excluding a further 63. 144 
57 articles were eligible for inclusion. 145 
 146 
 There was only one disagreement between raters which was resolved by a third 147 
reviewer (VEP). The review followed PRISA systematic review guidelines (PRISMA 148 
checklist in Supplementary Table 2). 149 
 150 
Figure 1. PRISMA flow chart 151 
 6 
 152 
 153 
Study characteristics 154 
 155 
There was a variety of study designs. Most were case-control studies, comparing 156 
those with AD or Mild Cognitive Impairment (MCI) to healthy controls [4,5,8–29]. 157 
Others were cross-sectional [20,21,30–58] and some were longitudinal [59–64]. The 158 
majority included participants of European ancestry from Europe, the US or 159 
Australia, although some included Black African American [39,44,45], Hispanic 160 
[5,40], Caribbean [5], or Han Chinese participants [13,22,57]. Sample size ranged 161 
from 66 [65] to over one hundred thousand [47]. The articles examined associations 162 
with several phenotypes. See Table 1 for a summary of study characteristics. 163 
 164 
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 166 
PRS Calculation 167 
 168 
All studies computed PRS using SNPs that have been associated with AD in large 169 
meta-analyses. Most used the International Genomics of Alzheimer’s Project (IGAP) 170 
[66] or another recent GWAS. There were two approaches to identifying SNPs for 171 
inclusion: 1) selecting SNPs that reached genome-wide significance in meta-172 
analysis, or 2) using p-value thresholds, including a greater number of nominally 173 
associated SNPs (please see Tables 3 and 4 in Supplementary Materials for a 174 
summary of PRS calculation). The number of studies using each approach is 175 
outlined in table 1. Two of the studies in Han Chinese populations choose to verify 176 
that the SNPs were associated with AD in their population before computing PRS 177 
[13,22]. Most studies weighted PRS by effect size, specifically the logarithm of the 178 
odds ratio or beta-coefficient from the regression analysis model, as described by 179 
Purcell and colleagues [67]. There were five exceptions: one study weighted by 180 
explained variance [37]; four studies created unweighted scores by summing the 181 
number of risk loci [39,52,68,69]. APOE was either included as a co-variate, included 182 
in the PRS or excluded (see Tables 3 and 4 in Supplementary Materials).  183 
 184 
Prediction of AD Case/Control Status  185 
 186 
15 studies used PRS to predict AD case/control status with various statistical 187 
approaches. Some studies used the area under the receiver operating characteristic 188 
(ROC) curve, whereas others used time-to-event analysis, Odds Ratios (OR) or a 189 
Table 1. Summary of included studies by type of PRS
Correlates/Outcomes N Studies
N Threshold 
PRS Studies
N GWAS Significant 
PRS Studies
AD risk prediction 15 5 10
MCI risk prediction or MCI conversion 4 2 2
MRI phenotypes 12 7 5
Cognition 21 5 16
CSF biomarkers 8 3 5
Other diseases/syndromes 4 2 2
Disease pathways 3 1 2
Acronyms: AD = Alzheimer's Disease; MCI = Mild Cognitive Impairment; MRI = Magnetic 
Resonance Imaging; CSF = Cerebrospinal Fluid; GWAS = Genome-wide Association Study.
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combination of methods. All found that PRS was able to discriminate cases from 190 
controls, although prediction accuracy varied.  191 
 192 
Of those studies reporting Area Under the Curve (AUC), five included APOE and 193 
achieved AUC ranging from 0.62–0.84 [12,15–17,22,70]. Four studies 194 
excluded APOE and achieved AUC ranging from 0.57–0.75 [12,25,30,71]. Of those 195 
studies using time-to-event analysis, all four excluded APOE and reported Hazard 196 
Ratios (HR) ranging from 1.11 – 2.36 [23,35,72]. Of those studies using ORs, two 197 
included APOE in their PRS and reported OR ranging from 2.06– 2.32 [73,74]. Four 198 
studies excluded APOE and reported OR ranging from 1.14–2.85 [5,25,30,75]. For 199 
more detailed information including the details of the samples and outcome 200 
measures used by each study, please see Tables 3 and 4 in Supplementary 201 
Materials. 202 
 203 
Mild Cognitive Impairment to AD conversion 204 
 205 
Eight studies assessed the ability of PRS to predict MCI to AD conversion. Three 206 
studies did not report statistically significant results [11,29,37]. Rodriguez-Rodriguez 207 
et al. compared those in the 1st and 3rd tertile of PRS (OR: 1.32, 95% CI: 0.57–3.06). 208 
Neither of the hazard models used by Lacour et al. and Andrews et al. produced 209 
significant results (Lacour HR: 1.18, 95% CI: 0.37–2.0; Andrews HR: 1.05, 95% CI: 210 
0.86-1.29)[29,37]. However, Andrews et al found their PRS was associated with an 211 
increased risk of transitioning from normal cognition to dementia (HR = 4.19, 95% CI: 212 
1.72-10.20) [37]. Five studies did report statistically significant results 213 
[18,33,35,58,64]. However, when APOE was removed, only one study remained 214 
positive [58]. An additional study evaluated genetic contributors to the Diagnostic 215 
and Statistical Manual IV (DSM-IV) diagnosis of Cognitive Impairment, No Dementia 216 
(CIND), which is similar to MCI. They found no significant difference in the frequency 217 
of risk alleles between cases and controls (p = 0.710) [27]. 218 
 219 
Cognitive Measures 220 
 221 
Cognition and PRS were examined in 21 studies [11,26,31,33,36,39,40,44,45,50–222 
52,54,56,57,60,62–64,69,76]. Whilst a variety of cognitive measures were used, all 223 
 9 
but four studies reported some significant associations with PRS. Most studies were 224 
in healthy older adults, although two studies included participants with established 225 
AD/MCI [11,26], two studies had young adult participants [57,77], one study had 226 
adolescent participants [40] and one included longitudinal data from children aged 11 227 
[59]. There were some cross-sectional studies that only reported associations with 228 
AD polygenic risk and cognition at one timepoint [40,50,52,54,55,57,69,77], whereas 229 
longitudinal studies were able to report the correlations with change in cognition over 230 
time [11,26,31,33,36,44,45,56,60,62–64]. As expected, most studies reported that 231 
the effects attenuated or were no longer significant when APOE was excluded from 232 
the PRS. Please see Supplementary Materials tables 3 and 4 for full details of 233 
cohorts and measures used. 234 
 235 
MRI phenotypes  236 
 237 
12 studies explored correlations between AD PRS and MRI phenotypes. Most 238 
studies looked at subcortical volumes [13,30,33,40,77]. Some also explored cortical 239 
thickness [41,56,74], white matter metrics [77], and functional MRI [13]. One study 240 
used algorithms that assess spatial atrophy patterns in AD [43]. Most studies 241 
sampled healthy older adults, although some included younger adults [57,77], 242 
adolescents [40], or a range of age groups [30]. Some studies included some 243 
participants with MCI or AD [13,30,33] and one study sampled military veterans with 244 
head injuries [56]. 245 
 246 
Of the six studies that explored subcortical volumes, all reported significant negative 247 
correlations between PRS and hippocampal volume [30,33,40,61,77,78]. One study 248 
only found a significant association in participants who were negative for amyloid on 249 
PET [28]. One study reported a significant negative association with amygdala 250 
volume [30] but only in participants with diagnoses of MCI or AD. A separate study 251 
trained an algorithm to detect the spatial patterns of healthy brain aging and atrophy 252 
in AD. They found a significant association AD PRS and the spatial pattern AD 253 
atrophy [43].   254 
 255 
Of those studies looking at cortical thickness [41,56,57,61,74], all but one [61] 256 
reported significant associations between increased PRS and cortical thinning. 257 
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Studies either reported associations with cortical thinning across multiple regions 258 
that are susceptible to AD pathology [41,56,74], or with cortical thinning is specific 259 
regions such as the precuneus [57]. 260 
 261 
One study assessed white matter, and identified reduced fractional anisotropy in the 262 
right cingulum with increasing PRS [77]. One study explored changes in the Default 263 
Mode Network and reported changes in functional connectivity in the left medial 264 
temporal gyrus and the right hippocampal/parahippocampal gyrus in those with MCI. 265 
However, there were no significant associations in healthy controls [13]. 266 
 267 
Amyloid and Tau Biomarkers  268 
 269 
Nine studies explored associations between PRS and amyloid and tau biomarkers 270 
[8–10,21,25,33,35,49,60]. They were all case/control studies. One study sampled 271 
those with autosomal dominant and sporadic AD [25]. Another included participants 272 
with normal pressure hydrocephalus [8]. The phenotypes included: CSF amyloid and 273 
tau measures [10,21,25,33,35,49]; post-mortem biomarkers or histology [8,10,35]; 274 
amyloid PET [33,35].  275 
 276 
A variety of analysis approaches were taken. Some studies assessed each tau and 277 
amyloid biomarker independently [9,10], whereas others created composite variables 278 
using CSF, PET or histology biomarkers [21,25,35,49].  279 
 280 
There were significant associations reported between AD PRS and the following: 281 
increased CSF tau and phosphorylated tau [9]; CSF A [10];  lower Aβ42/Aβ40 [49]; 282 
higher t-tau/Aβ42 and higher p-tau/Aβ42 ratio [25,49]; positive A PET [33]; total 283 
PET/CSF amyloid load and tau load [35]; post-mortem soluble Aβ42 and -secretase 284 
activity [10]; post-mortem amyloid plaques and neurofibrillary tangles [60]. Some 285 
studies did not report significant associations between AD PRS and CSF tau [10,33] 286 
or CSF A [9,33]. There was also no association with microglial density on post-287 
mortem histology [60] or amyloid deposition in brain biopsies of Normal Pressure 288 
Hydrocephalus patients [8]. One study combined CSF biomarkers with PRS to 289 
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predict AD, but the PRS did not improve prediction over and above the CSF amyloid 290 
and tau [21]. 291 
 292 
Other diseases and syndromes 293 
 294 
Other studies have explored associations between AD PRS and other disorders or 295 
syndromes. Pilling and colleagues reported significant negative correlations with 296 
longevity [47], and red cell volume, a measure of anaemia [48]. However there were 297 
no significant associations reported with depression [53] or post-concussive 298 
syndrome [20]. 299 
 300 
Disease pathways 301 
 302 
Four studies explored patterns associations between AD pathway PRS and disease-303 
related phenotypes. Each study used sets of SNPs based on previous pathway 304 
analyses in AD [6,79]. Some used only Bonferroni-significant loci [23,41,42], 305 
whereas others used a threshold-based PRS [32]. Various phenotypes were 306 
assessed including: MCI risk [23], MRI phenotypes [23,41], cognition [42], CSF Aβ 307 
and tau [42], Aβ PET [42] and complement markers [32].  308 
 309 
Using PRS for the immune response, endocytosis, cholesterol transport, 310 
hematopoietic cell lineage, protein ubiquitination, hemostasis, clathrin/AP2 adaptor 311 
complex, and protein folding pathway, Ahmad et al reported the immune response 312 
and clathrin/AP2 adaptor complex pathways showed nominal associations with white 313 
matter lesions, but this did not withstand correction for multiple testing. The 314 
endocytosis risk score was significantly associated with risk of MCI [23]. Darst et al 315 
used PRS for amyloid β clearance, cholesterol metabolism, and the immune 316 
response. They found no association between cognition and any PRS, even when 317 
APOE was included [42]. A higher Aβ clearance PRS and cholesterol PRS was 318 
associated with lower CSF Aβ42, a narrower Aβ42/Aβ40 ratio, and greater Aβ PET 319 
deposition. With APOE excluded, the only significant associations were between the 320 
cholesterol PRS and CSF Aβ42/Aβ40 and the immune response PRS and CSF tau, 321 
though not when corrected for multiple comparisons [42].  322 
 323 
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Two studies focused on the immune response PRS. Corlier et al found that the 324 
immune response PRS was significantly associated with an overall measure of 325 
cortical thinning [41]. Morgan et al reported that clusterin, C1 inhibitor, and c-reactive 326 
protein all showed nominal association with the inflammation-specific PRS. Plasma 327 
clusterin levels were associated with the overall AD PRS [32]. 328 
 329 
Study quality 330 
 331 
Overall, the articles had clear research questions and used adequate methodology. 332 
Some studies used small sample sizes [32,49,52,65] and many studies failed to 333 
describe sample ascertainment clearly. They used standard outcome measures. Of 334 
those looking at AD prediction, all but two [14,22] reporting using NINDS-ADRDA 335 
diagnostic criteria for AD. Most studies weighted PRS by effect size or odds ratio, 336 
although in some studies this was not clearly described [14,22]. Some studies had 337 
some overlap between training and validation datasets which may have inflated their 338 
results. Most studies attempted to assess the contribution of APOE by either 339 
excluding it from the PRS or including it as a co-variate. Some studies included 340 
cohorts of non-European ancestry [22,39,44,45,71]. These studies acknowledged 341 
that: i) they may have had insufficient power in their non-European samples or ii) 342 
PRS based on GWAS conducted in European populations may not capture AD 343 
genetic risk among those of non-European descent.  344 
 345 
 346 
 347 
DISCUSSION  348 
 349 
This paper systematically reviews how AD PRS are associated with a range of 350 
phenotypes and outcomes. Other papers have covered PRS methodology [3] and 351 
some have reviewed the use of PRS in AD prediction alone [80].  352 
 353 
Since the advent of large-scale genetics consortia such as the International 354 
Genomics of Alzheimer’s Project (IGAP), our understanding of the genetic 355 
underpinnings of AD has rapidly expanded. GWAS have resulted in the identification 356 
of over 20 novel genetic risk loci in addition to APOE ε4 [2,81]. Most of these SNPs 357 
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only increase AD risk incrementally. Therefore, combining SNPs into PRS has 358 
proved an important strategy for studying their effects. Some of the studies included 359 
in this review used only the most significant loci in their PRS. However, more recent 360 
studies used liberal threshold-based PRS computed from thousands of AD risk loci. 361 
 362 
PRS in disease prediction 363 
 364 
AD PRS have demonstrated strong predictive ability. Conservative PRS, including 365 
only genome-wide significant SNPs, have achieved reasonable prediction accuracy 366 
(AUC range: 57–72%) [4,25,70,71,73].  Threshold-based PRS, including many more 367 
SNPs, have proved superior to both conservative PRS and to APOE alone (AUC 368 
75%)[4]. Prediction accuracy is even greater using a threshold-based PRS in 369 
histologically confirmed cases and controls (AUC 84%) [17]. The findings for MCI 370 
conversion prediction are more mixed. Of the three studies reporting negative 371 
results, two had relatively low power [11,82]. Almost all the studies exploring PRS 372 
prediction accuracy report that there is some overlap between cases and controls at 373 
high polygenic risk. Moreover, in the absence of therapeutic consequences, the 374 
clinical utility of these findings remains limited.  375 
 376 
Associations between AD PRS, phenotypes and biomarkers 377 
 378 
Overall, the evidence from cross-sectional, case-control and longitudinal cohort 379 
studies pointed towards an association between PRS and a range of AD-related 380 
phenotypes. Of these, cognition has been the most widely investigated. Whilst the 381 
methodology and samples were diverse, the vast majority of studies reported 382 
significant associations [11,26,31,33,36,40,44,45,50,52,54,56,60,63,64,69,70]. Of 383 
the negative studies, one used a threshold-based PRS [59] and another used a PRS 384 
including 15 Bonferroni-significant risk SNPs [39] but both excluded APOE entirely. 385 
The other two negative studies both used samples of young adults [57,77], 386 
suggesting that cognitive changes related to AD genetic risk may not manifest until 387 
later in life.  388 
 389 
There was consistent evidence to support an association between AD PRS and 390 
changes in brain structure, particularly in decreased hippocampal volume 391 
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[30,33,40,61,77,78] and reduced cortical thickness [41,56,57,61,74]. This was 392 
reported even in samples of young adults,[40,51] suggesting that AD risk may 393 
manifest in brain structure decades before the onset of disease. These studies 394 
provide also found that the threshold based PRS yielded better results. For example, 395 
Mormino et al found an association between a threshold PRS and hippocampal 396 
volume that was not present when only genome-wide significant SNPs were used 397 
[33]. 398 
 399 
There were mixed findings for amyloid and tau biomarkers. Of those studies 400 
exploring CSF, PET or histology biomarkers, all but one reported statistically 401 
significant associations. However, findings were not consistent across biomarkers. 402 
For example, one study reported an association between CSF tau and 403 
phosphorylated tau but not A [9], whereas another study found the reverse [10]. 404 
Another study reported a significant association with A PET but not with CSF A or 405 
tau [33]. However, studies with post-mortem samples did find evidence of 406 
association between AD PRS and soluble Aβ42 levels, -secretase activity [10], 407 
neuritic amyloid plaques and neurofibrillary tangles [60]. PRS for other 408 
neuropsychiatric disorders were not associated [60]. Moreover, AD PRS was not 409 
associated with amyloid accumulation in Normal Pressure Hydrocephalus [8]. This 410 
suggests that the genetic foundations of amyloid deposition in other conditions may 411 
be distinct from those in AD. In addition, there was no evidence for pleiotropy 412 
between AD and depression [53]. 413 
 414 
 415 
PRS in disease pathways 416 
 417 
GWAS have resulted in the identification of novel genetic risk loci in addition to 418 
APOE ε4,[2,81] which have been associated with a range of biological pathways 419 
including lipid metabolism, immune response, and synaptic processes [79,83]. AD is 420 
heterogeneous and multifactorial. Polygenic profiling can allow individual molecular 421 
sub-classification, by identifying the pathways enriched for risk alleles for an 422 
individual. Four of the most recent studies included in this review took this approach, 423 
suggesting that the field is moving in this direction. They found some evidence for 424 
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association between pathway-specific polygenic scores and MCI risk [23], cognition 425 
[42], brain structure [23,41], CSF biomarkers [42], Aβ PET [42] and serum 426 
complement markers [32]. The variance that each of these pathways explains is 427 
small [42]. This will probably increase as discovery sample sizes increase [84], but 428 
will be restricted as PRS do not capture the contributions of copy number variant or 429 
rare SNPs. 430 
 431 
Pathway-specific polygenic profiling could enable personalized treatment of each 432 
individual with AD. This could allow entrants to clinical trials and biomarker studies to 433 
be stratified based on evidence of involvement of specific disease pathways. 434 
Moreover, if polygenic risk profiles can give prognostic information, they may aid 435 
decision making for individuals and clinicians. For example, a high PRS has been 436 
associated with a more accelerated progression from MCI to AD [11].  437 
 438 
Strengths and limitations 439 
 440 
We used a systematic and comprehensive search strategy to avoid missing eligible 441 
studies. However, we were not able to include studies that were not in English-442 
language journals. Another strength is that articles were not limited to a particular 443 
sampling framework or research design (e.g. longitudinal studies or clinical 444 
samples), or to European ancestry samples. We also included studies investigating 445 
broad ranges of outcomes which enhanced our ability to assess how AD polygenic 446 
risk is manifest. However, results were not reported consistently across studies, 447 
meaning only a narrative review was feasible, and we were not able to assess for 448 
publication bias. 449 
 450 
We identified a number of limitations in the studies included in this review. In order to 451 
conduct a polygenic score analysis, two completely independent datasets are 452 
required. Any overlap in the datasets will inflate the associations found. Some 453 
studies appeared to use sub-samples of the discovery sample as target samples and 454 
not all attempted to account for this. Some studies also appeared to be 455 
underpowered. Authors often did not provide a clear description of sample 456 
ascertainment, making it harder to put their findings into the context of the wider 457 
literature. Standardized effect estimates or confidence intervals were also often 458 
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omitted, which are required to compare effect sizes across studies. We have 459 
previously proposed a reporting framework for studies which might assist future 460 
researchers who synthesize data across such studies [85]. 461 
 462 
Some studies explored similar phenotypes in comparable samples but reported 463 
different results. Heterogeneity may stem from the PRS or the study design. 464 
Regarding the PRS, the exact list of SNPs is likely to differ between studies. Some 465 
researchers selected SNPs that reached genome-wide significance, and others used 466 
a p-value threshold approach, a key distinction. With threshold based PRS, 467 
experimenters exclude SNPs with low imputation quality scores. These vary 468 
depending on the array, imputation platform and pre- and post- imputation quality 469 
control steps. In addition, even small differences in population genetics may lead to 470 
distinctive linkage disequilibrium (LD) structure and allele frequencies [86]. Pruning, 471 
an essential part of PRS calculation, relies on LD structure to retain SNPs that are 472 
most associated with a trait whilst removing others that are closely linked. Where LD 473 
structure diverges, alternative SNPs will be selected. Furthermore, in disease 474 
pathway PRS, the gene sets are determined by the databases used to define the 475 
pathways. Regarding study design, there are other potential causes of 476 
heterogeneity. There may be discrepancies in how phenotypes are defined or 477 
measured, and different approaches to data analysis. Finally, there are possible 478 
sources of bias. For example, disease prediction studies using PRS can be affected 479 
by selection bias. If the target dataset is enriched for AD or MCI cases, this will affect 480 
the prediction accuracy. 481 
 482 
CONCLUSIONS 483 
 484 
PRS approach is an important approach used for capturing the contribution of 485 
genome wide common variation of complex diseases. To the best of our knowledge, 486 
this is the first review attempting to collate information on how the use of the PRS 487 
approach has informed our understanding of a variety of phenotypes associated with 488 
AD genetic risk. PRS can predict AD and are associated with cognitive impairment. 489 
There is also evidence of association between AD PRS and other phenotypes 490 
relevant to neurodegeneration. The associations between pathway specific PRS and 491 
phenotypic changes may allow us to define the biology of the disease in individuals, 492 
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heralding precision medicine in AD. However, longitudinal cohort studies are 493 
required to test the ability of PGS to delineate pathway-specific disease activity. In 494 
the absence of therapeutic consequences, the clinical utility of PRS is limited. 495 
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